Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
The originally published version of this Article contained errors in Figure 4. In panel b, the square and diamond labels associated with the uppermost survival curve were incorrectly displayed as ‘n’ and ‘u’, respectively. These errors have now been corrected in both the PDF and HTML versions of the...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2018-01-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-017-02205-9 |
| _version_ | 1818841311309987840 |
|---|---|
| author | Pengju Wang Xiaozhu Li Jiwei Wang Dongling Gao Yuenan Li Haoze Li Yongchao Chu Zhongxian Zhang Hongtao Liu Guozhong Jiang Zhenguo Cheng Shengdian Wang Jianzeng Dong Baisui Feng Louisa S Chard Nicholas R Lemoine Yaohe Wang |
| author_facet | Pengju Wang Xiaozhu Li Jiwei Wang Dongling Gao Yuenan Li Haoze Li Yongchao Chu Zhongxian Zhang Hongtao Liu Guozhong Jiang Zhenguo Cheng Shengdian Wang Jianzeng Dong Baisui Feng Louisa S Chard Nicholas R Lemoine Yaohe Wang |
| author_sort | Pengju Wang |
| collection | DOAJ |
| description | The originally published version of this Article contained errors in Figure 4. In panel b, the square and diamond labels associated with the uppermost survival curve were incorrectly displayed as ‘n’ and ‘u’, respectively. These errors have now been corrected in both the PDF and HTML versions of the Article. |
| first_indexed | 2024-12-19T04:24:04Z |
| format | Article |
| id | doaj.art-480ad26356494b4ba55bf572179933af |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-12-19T04:24:04Z |
| publishDate | 2018-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-480ad26356494b4ba55bf572179933af2022-12-21T20:36:04ZengNature PortfolioNature Communications2041-17232018-01-01911110.1038/s41467-017-02205-9Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agentPengju Wang0Xiaozhu Li1Jiwei Wang2Dongling Gao3Yuenan Li4Haoze Li5Yongchao Chu6Zhongxian Zhang7Hongtao Liu8Guozhong Jiang9Zhenguo Cheng10Shengdian Wang11Jianzeng Dong12Baisui Feng13Louisa S Chard14Nicholas R Lemoine15Yaohe Wang16Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversityCAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of SciencesSino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversitySino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversitySino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversitySino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversitySino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversitySino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversitySino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversitySino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversitySino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversityCAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of SciencesDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou UniversitySino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversityCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of LondonSino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversitySino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversityThe originally published version of this Article contained errors in Figure 4. In panel b, the square and diamond labels associated with the uppermost survival curve were incorrectly displayed as ‘n’ and ‘u’, respectively. These errors have now been corrected in both the PDF and HTML versions of the Article.https://doi.org/10.1038/s41467-017-02205-9 |
| spellingShingle | Pengju Wang Xiaozhu Li Jiwei Wang Dongling Gao Yuenan Li Haoze Li Yongchao Chu Zhongxian Zhang Hongtao Liu Guozhong Jiang Zhenguo Cheng Shengdian Wang Jianzeng Dong Baisui Feng Louisa S Chard Nicholas R Lemoine Yaohe Wang Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent Nature Communications |
| title | Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent |
| title_full | Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent |
| title_fullStr | Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent |
| title_full_unstemmed | Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent |
| title_short | Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent |
| title_sort | author correction re designing interleukin 12 to enhance its safety and potential as an anti tumor immunotherapeutic agent |
| url | https://doi.org/10.1038/s41467-017-02205-9 |
| work_keys_str_mv | AT pengjuwang authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT xiaozhuli authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT jiweiwang authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT donglinggao authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT yuenanli authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT haozeli authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT yongchaochu authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT zhongxianzhang authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT hongtaoliu authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT guozhongjiang authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT zhenguocheng authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT shengdianwang authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT jianzengdong authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT baisuifeng authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT louisaschard authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT nicholasrlemoine authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT yaohewang authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent |